Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has entered into a licensing agreement with Taiwan-based Orient EuroPharma Co., Ltd for the immunotherapy drug oregovomab. The agreement grants Orient exclusive commercialization rights to oregovomab in Taiwan, with additional preemptive rights for exclusive sales, marketing, and distribution in Hong Kong and Macau.
Financial Terms and Commercialization Rights
Under the terms of the agreement, Orient will pay an undisclosed upfront payment to OncoVent, along with milestone payments that could total up to USD 11.2 million. Orient will also purchase the drug from OncoVent at a negotiated proportion of the average selling price of oregovomab in Taiwan.
Clinical Progress and Efficacy of Oregovomab
Oregovomab, a first-in-class monoclonal antibody targeting CA125, is currently in the global Phase III clinical stage. The recently concluded Phase II clinical study for oregovomab in combination with chemotherapy for first-line advanced primary ovarian cancer has demonstrated promising safety and efficacy. The study showed that the median progression-free survival (PFS) in the combination therapy group was significantly prolonged, reaching 41.8 months, compared to 12.2 months in the chemotherapy-alone group, with a risk ratio (HR) of 0.46 (95% confidence interval: 0.28, 0.77). Moreover, overall survival (OS) also saw a significant improvement, with an HR of 0.35 (95% confidence interval: 0.16, 0.76).-Fineline Info & Tech
